Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options.
Protara Therapeutics has raised $75.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Protara Therapeutics's investors include RA Capital Management, Catalio Capital Management, Armistice Capital, Red Cedar Ventures, Woodline Partners.
Protara Therapeutics is headquartered in New York, United States.
Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options.
Protara Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Protara Therapeutics — Funding & Investors." VCBacked, December 4, 2025, https://www.vcbacked.co/company/protara-therapeutics. Accessed November 11, 2026.
VCBacked. (2025). Protara Therapeutics — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/protara-therapeutics
{{cite web |title=Protara Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/protara-therapeutics |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Protara Therapeutics? Request a listing update